Bahl & Gaynor Inc. Has $11.26 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. trimmed its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,247 shares of the medical instruments supplier's stock after selling 7,081 shares during the quarter. Bahl & Gaynor Inc. owned about 0.54% of LeMaitre Vascular worth $11,264,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in shares of LeMaitre Vascular by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier's stock worth $18,037,000 after buying an additional 4,241 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of LeMaitre Vascular by 2.8% in the 4th quarter. Jones Financial Companies Lllp now owns 6,987 shares of the medical instruments supplier's stock worth $644,000 after purchasing an additional 187 shares in the last quarter. Norden Group LLC raised its holdings in shares of LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock worth $218,000 after purchasing an additional 103 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 293 shares in the last quarter. Finally, Flputnam Investment Management Co. raised its holdings in shares of LeMaitre Vascular by 3.6% in the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock worth $269,000 after purchasing an additional 102 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $95.25.

LeMaitre Vascular Stock Down 1.4 %

Shares of LMAT stock traded down $1.12 during trading hours on Friday, reaching $81.37. 454,449 shares of the stock traded hands, compared to its average volume of 141,274. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58. The business has a fifty day moving average price of $96.29 and a 200 day moving average price of $94.83. The firm has a market capitalization of $1.84 billion, a PE ratio of 44.46, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, March 13th. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.